MedTrace Logo

Study of Everolimus (RAD001) in Combination With Lenalidomide

NCT01218555 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-01-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to study the combination of two anticancer drugs, everolimus (RAD001) and lenalidomide in patients whose cancer is no longer responding to standard treatment or patients who are unable to tolerate the standard treatment for their cancer.

Conditions

Interventions

DRUG

Lenalidomide

Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.

DRUG

Everolimus

5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • Emory University

    lead OTHER

Principal Investigators

  • Taofeek Owonikoko, PhD/MD · Emory University Winship Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-09
Primary Completion
2020-11-05
Completion
2020-11-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218555 on ClinicalTrials.gov